Xenon Pharmaceuticals (XENE) FCF Margin (2013 - 2025)

Xenon Pharmaceuticals (XENE) has 10 years of FCF Margin data on file, last reported at 822.6% in Q1 2025.

• On a quarterly basis, FCF Margin changed N/A year-over-year to 822.6% in Q1 2025; TTM through Dec 2025 was 3732.23%, a N/A change from a year earlier, with the FY2025 full-year figure at 3732.23%, changed N/A from the prior year.
• FCF Margin for Q1 2025 stood at 822.6%, up from 23324.24% in the prior quarter.
• Over the last five years, FCF Margin for XENE reached as high as 187.47% in Q3 2021 and fell as low as 23324.24% in Q3 2022.
• Historically, FCF Margin has averaged 3684.8% across 3 years, with a median of 599.26% in 2021.
• On a YoY basis, FCF Margin climbed as much as 27180 bps in 2022 and fell as far as 2313677 bps in 2022.
• Year by year, FCF Margin stood at 567.94% in 2021, then tumbled by 4007 bps to 23324.24% in 2022, then soared by 96 bps to 822.6% in 2025.
• Per Business Quant data, the three most recent FCF Margin figures were 822.6% in Q1 2025, 23324.24% in Q3 2022, and 3248.51% in Q2 2022.